Webinar presenter Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer, PathGroup, discusses the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer.
This on-demand webinar was originally broadcast on May 21, 2025.
What will this webinar empower you to do?
• Understand the clinical significance of identifying patients with certain low levels
of HER2 in metastatic breast cancer
• Understand the evolution of the HER2 spectrum
• Highlight key considerations that impact HER2 IHC scoring and interpretation
• Review guidance for pathologists to accurately report HER2 status
• Ask questions of our distinguished presenter
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within.
This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation. In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company sponsored programs. Please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you may receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity that limits or prohibits meals from pharmaceutical companies, please identify yourself so that compliance with such requirements can be ensured.
PP-US-8201a-2374 04/25